According to filings with the U.S. Securities and Exchange Commission, Novel Microdevices is raising $6,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Andrea Pais played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Novel Microdevices
Novel Dx detects the genetic material of pathogens using Nucleic Acid Amplification techniques. These are the same methods that are utilized in large reference laboratories. Novel Dx delivers lab-quality results in under 30 minutes so patients can be tested and treated in the same visit. Novel Microdevices rapid point-of-care diagnostic is designed for portability, weighing only four pounds. It is battery-powered, making it particularly suited to low resource settings and low-and middle-income countries (LMICs). The molecular testing platform implements polymerase chain reaction (PCR) technology on a disposable cartridge. The patient sample is added to the cartridge, which is then inserted into the Novel Dx system, which analyzes the genetic sequence of cells to identify disease and the presence of genetic mutations known to make bacteria resistant to antibiotics.

To learn more about Novel Microdevices, visit http://noveldx.com/

Contact:
Andrea Pais, Chief Executive Officer
352-642-2391
https://www.linkedin.com/in/andrea-pais-4a839a62/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.